- Home
- COYA vs STTK Comparison
COYA vs STTK Comparison
Compare COYA & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | STTK |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 119.0M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | COYA | STTK |
|---|---|---|
| Price | $4.51 | $4.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $15.80 | $4.00 |
| AVG Volume (30 Days) | 315.7K | ★ 649.0K |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,987,706.00 | $1,000,000.00 |
| Revenue This Year | $70.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.94 | $0.69 |
| 52 Week High | $8.29 | $4.89 |
Technical Indicators
Market Signals| Indicator | COYA | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 61.27 |
| Support Level | $3.94 | $4.25 |
| Resistance Level | $4.95 | $4.80 |
| Average True Range (ATR) | 0.45 | 0.38 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 25.59 | 63.01 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.